About Baxter International (NYSE:BAX)
Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BAX
CUSIP07181310
Phone224-948-2000
Debt
Debt-to-Equity Ratio0.38%
Current Ratio2.57%
Quick Ratio2.05%
Price-To-Earnings
Trailing P/E Ratio27.83
Forward P/E Ratio24.94
P/E Growth1.81
Sales & Book Value
Annual Sales$10.56 billion
Price / Sales3.55
Cash Flow$4.1115 per share
Price / Cash16.86
Book Value$16.73 per share
Price / Book4.14
Profitability
EPS (Most Recent Fiscal Year)$2.48
Net Income$717 million
Net Margins6.79%
Return on Equity15.11%
Return on Assets8.18%
Miscellaneous
Employees47,000
Outstanding Shares540,140,000
Baxter International (NYSE:BAX) Frequently Asked Questions
What is Baxter International's stock symbol?
Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."
How often does Baxter International pay dividends? What is the dividend yield for Baxter International?
Baxter International declared a quarterly dividend on Tuesday, February 20th. Investors of record on Friday, March 2nd will be given a dividend of $0.16 per share on Monday, April 2nd. This represents a $0.64 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Thursday, March 1st. View Baxter International's Dividend History.
How will Baxter International's stock buyback program work?
Baxter International declared that its Board of Directors has approved a stock buyback program on Wednesday, February 21st 2018, which authorizes the company to buyback $1,500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's leadership believes its shares are undervalued.
How were Baxter International's earnings last quarter?
Baxter International (NYSE:BAX) posted its quarterly earnings data on Thursday, April, 26th. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.62 by $0.08. The medical instruments supplier had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.62 billion. Baxter International had a return on equity of 15.11% and a net margin of 6.79%. The business's quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.58 EPS. View Baxter International's Earnings History.
When is Baxter International's next earnings date?
What guidance has Baxter International issued on next quarter's earnings?
Baxter International issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $2.85-2.93 for the period, compared to the Thomson Reuters consensus estimate of $2.78. The company issued revenue guidance of $11.3-11.4 billion, compared to the consensus revenue estimate of $11.25 billion.Baxter International also updated its Q2 guidance to $0.69-0.71 EPS.
What price target have analysts set for BAX?
16 brokerages have issued 1-year price objectives for Baxter International's stock. Their predictions range from $62.00 to $80.00. On average, they expect Baxter International's stock price to reach $70.9286 in the next year. View Analyst Ratings for Baxter International.
Who are some of Baxter International's key competitors?
Some companies that are related to Baxter International include 3M (MMM), Stryker (SYK), Becton Dickinson (BDX), Fresenius (FSNUY), Boston Scientific (BSX), ResMed (RMD), Abiomed (ABMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Cantel Medical (CMD) and Penumbra (PEN).
Who are Baxter International's key executives?
Baxter International's management team includes the folowing people:
- Mr. José E. Almeida, Chairman, Pres & CEO (Age 56)
- Mr. James K. Saccaro, Exec. VP & CFO (Age 45)
- Mr. Brik V. Eyre, Sr. VP & Pres of Americas (Age 54)
- Mr. Giuseppe Accogli, Sr. VP & Pres of Global Bus.es (Age 47)
- Mr. Scott Pleau, Sr. VP of Operations (Age 52)
Has Baxter International been receiving favorable news coverage?
News headlines about BAX stock have trended positive on Thursday, Accern Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Baxter International earned a daily sentiment score of 0.39 on Accern's scale. They also gave news coverage about the medical instruments supplier an impact score of 47.17 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Baxter International?
Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Baxter International's stock price today?
One share of BAX stock can currently be purchased for approximately $69.29.
How big of a company is Baxter International?
Baxter International has a market capitalization of $35.73 billion and generates $10.56 billion in revenue each year. The medical instruments supplier earns $717 million in net income (profit) each year or $2.48 on an earnings per share basis. Baxter International employs 47,000 workers across the globe.
How can I contact Baxter International?
Baxter International's mailing address is One Baxter Parkway, DEERFIELD IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected]
MarketBeat Community Rating for Baxter International (BAX)
MarketBeat's community ratings are surveys of what our community members think about Baxter International and other stocks. Vote "Outperform" if you believe BAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Baxter International (NYSE:BAX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
16 Wall Street analysts have issued ratings and price targets for Baxter International in the last 12 months. Their average twelve-month price target is $70.9286, suggesting that the stock has a possible upside of 2.32%. The high price target for BAX is $80.00 and the low price target for BAX is $62.00. There are currently 6 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.69 | 2.69 | 2.67 | 2.58 |
| Ratings Breakdown: | 0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $70.9286 | $70.9286 | $68.3846 | $66.5833 |
| Price Target Upside: | 2.32% upside | 6.93% upside | 1.81% upside | 2.55% upside |
Baxter International (NYSE:BAX) Consensus Price Target History
Baxter International (NYSE:BAX) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Baxter International (NYSE:BAX) Dividend Information
Baxter International pays an annual dividend of $0.64 per share, with a dividend yield of 0.92%. BAX's most recent quarterly dividend payment was Monday, April 2. Baxter International pays out 25.81% of its earnings out as a dividend.
| Most Recent Dividend: | 4/2/2018 |
| Annual Dividend: | $0.64 |
| Dividend Yield: | 0.92% |
| Dividend Growth: | -34.00% (3 Year Average) |
| Payout Ratio: | 25.81% (Trailing 12 Months of Earnings)
23.02% (Based on This Year's Estimates)
20.38% (Based on Next Year's Estimates)
|
| Frequency: | Quarterly Dividend |
Baxter International (NYSE:BAX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/20/2018 | Quarterly | $0.16 | 0.95% | 3/1/2018 | 3/2/2018 | 4/2/2018 |
| 11/14/2017 | quarterly | $0.16 | 0.99% | 11/30/2017 | 12/1/2017 | 1/2/2018 |
| 7/18/2017 | quarterly | $0.16 | 1.03% | 8/30/2017 | 9/1/2017 | 10/2/2017 |
| 5/2/2017 | quarterly | $0.16 | 1.14% | 5/31/2017 | 6/2/2017 | 7/3/2017 |
| 2/21/2017 | quarterly | $0.13 | 1.04% | 3/1/2017 | 3/3/2017 | 4/3/2017 |
| 11/8/2016 | quarterly | $0.13 | 1.12% | 11/30/2016 | 12/2/2016 | 1/3/2017 |
| 7/19/2016 | quarterly | $0.13 | 1.11% | 8/31/2016 | 9/2/2016 | 10/3/2016 |
| 5/3/2016 | quarterly | $0.13 | 1.15% | 6/1/2016 | 6/3/2016 | 7/1/2016 |
| 2/16/2016 | quarterly | $0.1150 | 1.23% | 3/2/2016 | 3/4/2016 | 4/1/2016 |
| 11/11/2015 | quarterly | $0.1150 | 1.21% | 12/2/2015 | 12/4/2015 | 1/4/2016 |
| 7/29/2015 | quarterly | $0.1150 | 1.15% | 9/2/2015 | 9/4/2015 | 10/1/2015 |
| 5/5/2015 | quarterly | $0.52 | 3.02% | 5/28/2015 | 6/1/2015 | 7/1/2015 |
| 2/17/2015 | quarterly | $0.52 | 3.04% | 3/9/2015 | 3/11/2015 | 4/1/2015 |
| 11/11/2014 | quarterly | $0.52 | 2.92% | 12/3/2014 | 12/5/2014 | 1/2/2015 |
| 7/22/2014 | quarterly | $0.52 | 2.71% | 9/3/2014 | 9/5/2014 | 10/1/2014 |
| 5/5/2014 | quarterly | $0.52 | 2.81% | 6/4/2014 | 6/6/2014 | 7/1/2014 |
| 2/18/2014 | quarterly | $0.49 | 2.84% | 3/5/2014 | 3/7/2014 | 4/1/2014 |
| 11/12/2013 | quarterly | $0.49 | 2.95% | 12/4/2013 | 12/6/2013 | 1/3/2014 |
| 7/23/2013 | quarterly | $0.49 | 2.66% | 9/4/2013 | 9/6/2013 | 10/1/2013 |
| 5/6/2013 | quarterly | $0.49 | 2.86% | 6/5/2013 | 6/7/2013 | 7/1/2013 |
| 2/19/2013 | quarterly | $0.45 | 2.67% | 3/6/2013 | 3/8/2013 | 4/1/2013 |
(Data available from 1/1/2013 forward)
Baxter International (NYSE BAX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.05%
Institutional Ownership Percentage: 85.34%
Baxter International (NYSE BAX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Peter S Hellman | Director | Sell | 3,760 | $64.74 | $243,422.40 | 25,522 |  |
| 3/28/2018 | James R Gavin III | Director | Sell | 18,750 | $64.56 | $1,210,500.00 | 36,398 | |
| 3/2/2018 | Carole J Shapazian | Director | Sell | 4,990 | $66.05 | $329,589.50 | | |
| 1/2/2018 | Giuseppe Accogli | SVP | Sell | 28,641 | $67.00 | $1,918,947.00 | | |
| 12/4/2017 | Jeanne K Mason | SVP | Sell | 33,350 | $65.25 | $2,176,087.50 | 124,609 | |
| 11/6/2017 | Third Point Llc | Director | Sell | 5,000,000 | $64.23 | $321,150,000.00 | | |
| 9/5/2017 | Thomas T Stallkamp | Director | Sell | 8,920 | $62.28 | $555,537.60 | 16,263 | |
| 8/25/2017 | John D Forsyth | Director | Sell | 9,440 | $61.76 | $583,014.40 | 32,444 | |
| 8/24/2017 | Carole J Shapazian | Director | Sell | 4,020 | $61.61 | $247,672.20 | 13,868 | |
| 8/17/2017 | Giuseppe Accogli | SVP | Sell | 12,670 | $60.96 | $772,363.20 | 33,286 | |
| 5/23/2017 | Carole J Shapazian | Director | Sell | 2,618 | $57.92 | $151,634.56 | 9,848 | |
| 5/9/2017 | Carole J Shapazian | Director | Sell | 3,760 | $55.89 | $210,146.40 | 16,226 | |
| 5/8/2017 | Brik V Eyre | SVP | Sell | 130,732 | $55.69 | $7,280,465.08 | 49,966 | |
| 4/10/2017 | Albert P L Stroucken | Director | Sell | 4,280 | $52.80 | $225,984.00 | 25,667 | |
| 3/29/2017 | James R Gavin III | Director | Sell | 4,280 | $51.72 | $221,361.60 | 34,980 | |
| 2/22/2017 | Peter S Hellman | Director | Sell | 4,280 | $49.81 | $213,186.80 | 24,420 | |
| 2/8/2017 | John D Forsyth | Director | Sell | 4,280 | $48.35 | $206,938.00 | 31,338 | |
| 5/23/2016 | Jose E Almeida | CEO | Buy | 11,691 | $42.75 | $499,790.25 | 11,691 | |
| 5/2/2016 | John D Forsyth | Director | Sell | 1,887 | $44.38 | $83,745.06 | 26,320 | |
| 4/4/2016 | John D Forsyth | Director | Sell | 1,887 | $41.75 | $78,782.25 | 26,315 | |
| 3/14/2016 | James R Gavin III | Director | Sell | 5,660 | $40.34 | $228,324.40 | 33,432 | |
| 2/17/2016 | Peter S. Hellman | Director | Sell | 5,660 | $38.35 | $217,061.00 | 17,520 | |
| 2/11/2016 | Kornelis J. Storm | Director | Sell | 5,660 | $35.98 | $203,646.80 | 19,191 | |
| 5/22/2015 | Carole J Shapazian | Director | Sell | 1,533 | $67.68 | $103,753.44 | | |
| 4/27/2015 | James R Gavin III | Director | Sell | 4,830 | $71.06 | $343,219.80 | | |
| 7/25/2014 | Carole J Shapazian | Director | Sell | 1,645 | $76.98 | $126,632.10 | | |
| 7/24/2014 | Thomas T Stallkamp | Director | Sell | 8,300 | $76.82 | $637,606.00 | | |
| 7/9/2014 | Ludwig Hantson | VP | Sell | 24,693 | $76.00 | $1,876,668.00 | | |
| 5/2/2014 | Carole Shapazian | Director | Sell | 5,680 | $75.28 | $427,590.40 | 5,146 | |
| 4/23/2014 | Kees Storm | Director | Sell | 5,760 | $72.45 | $417,312.00 | 15,156 | |
| 4/21/2014 | Blake Devitt | Director | Sell | 4,334 | $73.12 | $316,902.08 | 16,541 | |
| 3/27/2014 | Sebastian Bufalino | VP | Sell | 21,600 | $75.10 | $1,622,160.00 | 6,275 | |
| 9/12/2013 | Carole Shapazian | Director | Sell | 1,941 | $71.58 | $138,936.78 | 5,111 | |
| 8/1/2013 | Robert L Parkinson Jr | CEO | Sell | 725,750 | $73.33 | $53,219,247.50 | | |
| 7/26/2013 | David P Scharf | VP | Sell | 55,438 | $73.79 | $4,090,770.02 | | |
| 7/25/2013 | James R Gavin III | Director | Sell | 5,760 | $72.82 | $419,443.20 | | |
| 7/24/2013 | Carole J Shapazian | Director | Sell | 4,320 | $73.58 | $317,865.60 | | |
| 7/22/2013 | Robert J Hombach | CFO | Sell | 47,452 | $73.95 | $3,509,075.40 | | |
| 7/16/2013 | Phillip L Batchelor | VP | Sell | 5,850 | $73.00 | $427,050.00 | | |
| 5/22/2013 | Blake E Devitt | Director | Sell | 1,000 | $72.34 | $72,340.00 | | |
| 5/20/2013 | Sebastian J Bufalino | VP | Sell | 24,000 | $73.75 | $1,770,000.00 | | |
| 5/17/2013 | Robert M Davis | VP | Sell | 130,800 | $73.00 | $9,548,400.00 | | |
| 9/13/2012 | Michael J Baughman | VP | Sell | 11,500 | $61.00 | $701,500.00 | | |
(Data available from 1/1/2013 forward)
Baxter International (NYSE BAX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Baxter Increases 2018 Financial Outlook - Quick Facts
www.nasdaq.com - April 26 at 9:42 AM |
 | Why Baxter International Inc (NYSE:BAX) Delivered An Inferior ROE Compared To The Industry
finance.yahoo.com - April 26 at 9:42 AM |
 | BRIEF-Baxter International Posts Q1 GAAP Earnings Per Share $0.71 From Continuing Operations
www.reuters.com - April 26 at 9:42 AM |
 | Baxter (BAX) Beats on Q1 Earnings and Revenue Estimates
www.zacks.com - April 26 at 9:42 AM |
 | Baxter International profit climbs 43%
www.marketwatch.com - April 26 at 9:42 AM |
| Baxter: 1Q Earnings Snapshot
finance.yahoo.com - April 26 at 9:42 AM |
 | Baxter International (BAX) Releases FY18 Earnings Guidance
www.americanbankingnews.com - April 26 at 9:32 AM |
| Baxter International (BAX) Releases Q2 Earnings Guidance
www.americanbankingnews.com - April 26 at 9:26 AM |
| Medical Product Stock Earnings Roster for Apr 26: BAX & More
finance.yahoo.com - April 25 at 4:14 PM |
| Global Hemophilia Treatment Market Competitive landscape: Baxter International Inc
www.marketwatch.com - April 25 at 10:15 AM |
| Baxter to Post 1Q18 Earnings on April 26: Can It Beat Estimates?
finance.yahoo.com - April 24 at 4:11 PM |
| [$$] Allied Healthcare lines up rescue plan
finance.yahoo.com - April 22 at 4:20 PM |
| Analysts Expect Baxter International (BAX) Will Announce Quarterly Sales of $2.62 Billion
www.americanbankingnews.com - April 21 at 4:20 AM |
| Baxter International (BAX) Rating Increased to Outperform at BMO Capital Markets
www.americanbankingnews.com - April 19 at 4:00 PM |
| Baxter International (BAX) Expected to Announce Earnings of $0.62 Per Share
www.americanbankingnews.com - April 19 at 11:15 AM |
| Baxter International (BAX) Set to Announce Earnings on Thursday
www.americanbankingnews.com - April 19 at 1:56 AM |
| Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?
www.zacks.com - April 17 at 9:52 AM |
| Cantor Fitzgerald Reiterates "$70.00" Price Target for Baxter International (BAX)
www.americanbankingnews.com - April 15 at 5:39 PM |
| Baxter International (BAX) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - April 15 at 12:36 AM |
| Edited Transcript of BAX presentation 7-Mar-17 12:30pm GMT
finance.yahoo.com - April 12 at 10:37 AM |
 | Multiple Tornadoes Spotted In Fort Lauderdale, Florida
www.msn.com - April 11 at 4:19 PM |
| Baxter International (BAX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 11 at 1:49 PM |
| Baxter International (BAX) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - April 10 at 4:28 PM |
| Abbott Laboratories Goes Ex-Dividend on April 12, 2018
finance.yahoo.com - April 10 at 4:13 PM |
| Global Sterile Injectable Market Opportunities 2018: Novartis AG, Sanofi S.A, Johnson & Johnson, Baxter International
www.marketwatch.com - April 10 at 10:05 AM |
| Baxter International (BAX) Receives "Hold" Rating from Royal Bank of Canada
www.americanbankingnews.com - April 8 at 11:01 AM |
| Baxter International (BAX) PT Set at $68.00 by Cowen
www.americanbankingnews.com - April 7 at 12:23 PM |
| Zacks Investment Research Downgrades Baxter International (BAX) to Hold
www.americanbankingnews.com - April 7 at 9:11 AM |
| Baxter International (BAX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 6 at 12:35 PM |
 | Global Artificial Blood and Plasma Markets to 2027: Leading Players are Alliance Pharma., Baxter Healthcare, Northfield Lab, Sanguine Biosciences, and Therapure Biopharma ...
www.businesswire.com - April 5 at 8:50 AM |
| Insider Selling: Baxter International Inc (BAX) Director Sells 3,760 Shares of Stock
www.americanbankingnews.com - April 4 at 10:56 PM |
| Baxter International (BAX) PT Raised to $62.00 at Morgan Stanley
www.americanbankingnews.com - April 4 at 7:30 PM |
| Baxter International (BAX) Price Target Increased to $73.00 by Analysts at Barclays
www.americanbankingnews.com - April 4 at 6:54 PM |
| Baxter to Host First Quarter 2018 Financial Results Conference Call for Investors
finance.yahoo.com - April 4 at 5:13 PM |
| Baxter International Inc (BAX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 4 at 10:44 AM |
| $2.62 Billion in Sales Expected for Baxter International Inc (BAX) This Quarter
www.americanbankingnews.com - April 4 at 3:58 AM |
| Baxter International (BAX) Lifted to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 6:58 PM |
| Baxter International (BAX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 3 at 2:58 PM |
| Baxter International Inc. to Host Webcast of Annual Meeting of Stockholders
finance.yahoo.com - April 3 at 10:05 AM |
| Brokerages Anticipate Baxter International Inc (BAX) to Announce $0.62 Earnings Per Share
www.americanbankingnews.com - April 2 at 9:10 AM |
| Bank of America Upgrades Baxter International (BAX) to Buy
www.americanbankingnews.com - March 31 at 11:54 AM |
| Baxter International (BAX) Upgraded by JPMorgan Chase to Overweight
www.americanbankingnews.com - March 31 at 11:54 AM |
 | Form 4 BAXTER INTERNATIONAL For: Mar 28 Filed by: STORM KORNELIS J.
www.streetinsider.com - March 31 at 9:40 AM |
| Baxter International (BAX) Coverage Initiated at Evercore ISI
www.americanbankingnews.com - March 30 at 11:40 PM |
| Discussing BDX’s Recent Stock Price Performance
finance.yahoo.com - March 30 at 4:16 PM |
| Baxter International Inc (BAX) Director James R. Gavin III Sells 18,750 Shares
www.americanbankingnews.com - March 30 at 4:14 PM |
| Baxter International (BAX) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 30 at 3:58 PM |
| Top Analyst Reports for Netflix, PNC Financial & Mondelez
finance.yahoo.com - March 29 at 4:13 PM |
| Baxter International Inc. -- Moody's upgrades Baxter International to Baa1 from Baa2, stable outlook
finance.yahoo.com - March 29 at 4:13 PM |
| Baxter International (BAX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 29 at 11:24 AM |
Baxter International (NYSE:BAX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Baxter International (NYSE:BAX) Income Statement, Balance Sheet and Cash Flow Statement
Baxter International (NYSE BAX) Stock Chart for Thursday, April, 26, 2018
Loading chart…
